Sabinsa opens new manufacturing facility in India for nutraceutical and active pharmaceutical ingredients
The new facility is located at Hassan in the State of Karnataka, India.
The inaugural opening of Sami-Sabinsa’s new Sami Nutraceuticals facility in Hassan, India. Photo from Sabinsa.
Sabinsa Corp.’s parent company, Sami-Sabinsa Group, has opened a new facility in India for manufacturing nutraceutical and active pharmaceutical ingredients. The new facility is located at Hassan in the State of Karnataka, India. The 10-acre site is Sami-Sabinsa’s eighth manufacturing facility.
Unit-1 of the facility, called Sami Nutraceuticals Pvt. Ltd., will produce ingredients like calebin-A, resveratrol, SabiWhite pterostilbene, urolithins, and more. The Sami Nutraceuticals facility includes sophisticated quality-control and process-development labs. “An important feature of this new facility is its Zero Liquid Discharge (ZLD) capability, which minimizes the production-associated ecological footprint,” the company said in a press release. The $18 million facility can produce 88 tons of active nutraceutical ingredients (ANI) and active pharmaceutical ingredients (API) per annum. The facility features 18 reactors (including eight glass-line reactors), two hydrogenators, and specialized equipment like agitated nutsche filter dryers (ANFD), centrifuges, and Rotocone vacuum dryers.
Unit-2 of the facility, built on 15 acres of land, is nearing completion. It will house three production blocks: one for curcumin production and two for multipurpose herbal extracts.
Judge in CRN’s complaint against NY denies the State’s motion to dismiss
May 14th 2024New York State's motion to dismiss CRN's lawsuit against the law banning the sale of weight management and muscle-building supplements to minors has been partially denied, allowing CRN to proceed with its First Amendment Claim.
